Galectin Therapeutics announced that a paper published in the peer-reviewed Journal for ImmunoTherapy of Cancer, the highest ranked fully open access immunology journal, provides further clinical evidence that using belapectin, a potent galectin-3 inhibitor, in combination with pembrolizumab, a PD-1 inhibitor, significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma and head and neck squamous cell carcinoma. The paper, titled "Enhancing Clinical and Immunological Effects of anti-PD-1 with Belapectin, a Galectin-3 Inhibitor" describes results from an ongoing Phase 1 clinical study, a collaboration between Galectin Therapeutics and Providence Cancer Institute in Portland, Oregon. Following the recent publication of positive preclinical results that showed the inhibition of galectin-3 in combination with an agonist anti-OX40 monoclonal antibody reprograms the tumor microenvironment to favor anti-tumor activity, the current study tests the clinical hypothesis that galectin-3 blockade with belapectin in combination with pembrolizumab enhances tumor response for patients with advanced MM or HNSCC. In the study, as previously disclosed, an objective response was observed in 50% of MM and 33% of HNSCC patients. This compares favorably to published response rates on pembrolizumab alone. The authors noted that the combination was associated with fewer immune-mediated adverse events than anticipated with pembrolizumab alone. In addition, the analysis of patients' tumor tissue revealed reduced monocytic myeloid-derived suppressor cells and increased effector memory T-cell activation in responders compared with non-responders. Also, an increased baseline expression of galectin-3 positive tumor cells correlated with clinical response.

In an updated statement, Johnson & Johnson said that it has made the decision to proactively delay the rollout of its COVID-19 vaccine in Europe and pause vaccinations in all Janssen COVID-19 vaccine clinical trials while it updates guidance for investigators and participants. "We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public," the company said. Reference Link